Hakan Kültürsay , Lale Tokgözoğlu , Taner Damcı , Aytekin Oğuz , Seçkin Pehlivanoğlu , Mustafa Şenocak , Mehmet Yusuf
{"title":"对土耳其人群中心血管高危患者进行5年随访。什么是最高心血管风险的预测因子?","authors":"Hakan Kültürsay , Lale Tokgözoğlu , Taner Damcı , Aytekin Oğuz , Seçkin Pehlivanoğlu , Mustafa Şenocak , Mehmet Yusuf","doi":"10.1016/j.cvdpc.2008.11.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Despite the overwhelming evidence from clinical trials showing that preventive measures recommended by recent guidelines significantly reduce mortality, the implementation rate in patients with high cardiovascular risk is still far from optimal.</p></div><div><h3>Methods</h3><p>A total of 5600 patients with a high cardiovascular risk were invited to participate however 3331 (59%) agreed to a five year follow-up in a multicenter, observational study. Primary end-points included death, myocardial infarction, stroke and optimal medication use over 5 years.</p></div><div><h3>Results</h3><p>Primary end-points including cardiovascular mortality were higher in patients with vascular disease (25.3% vs 15.1%, <em>p</em> <!--><<!--> <!-->0.001, and 13.5 vs 6.2%, <em>p</em> <!--><<!--> <!-->0.001, respectively) and it was doubled in 5 years. Presence of end organ damage further increased the incidence of primary end-point and cardiovascular mortality (30.6% vs 16.2%, <em>p</em> <!--><<!--> <!-->0.001 and 18.1% vs 6.8%, <em>p</em> <!--><<!--> <!-->0.001, respectively). The optimal preventive treatment (statin, renin-angiotensin system blocker, beta-blocker and antiplatelet) rate was low and did not change significantly in 5 years, although the consistent use of angiotensin-converting enzyme inhibitor seemed to be a protective predictor of cardiovascular mortality.</p></div><div><h3>Conclusion</h3><p>In this high risk Turkish population, mortality and morbidity in the medium to long term were high and the implementation rate of optimal preventive treatment unacceptably low. The highest risk subgroup was identified to be those with previous vascular disease/event and end organ damage requiring aggressive medical treatment.</p></div>","PeriodicalId":11021,"journal":{"name":"Cvd Prevention and Control","volume":"4 2","pages":"Pages 131-138"},"PeriodicalIF":0.0000,"publicationDate":"2009-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cvdpc.2008.11.001","citationCount":"1","resultStr":"{\"title\":\"Five year follow-up of patients with high cardiovascular risk in the Turkish population. What are the predictors of highest cardiovascular risk?\",\"authors\":\"Hakan Kültürsay , Lale Tokgözoğlu , Taner Damcı , Aytekin Oğuz , Seçkin Pehlivanoğlu , Mustafa Şenocak , Mehmet Yusuf\",\"doi\":\"10.1016/j.cvdpc.2008.11.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Despite the overwhelming evidence from clinical trials showing that preventive measures recommended by recent guidelines significantly reduce mortality, the implementation rate in patients with high cardiovascular risk is still far from optimal.</p></div><div><h3>Methods</h3><p>A total of 5600 patients with a high cardiovascular risk were invited to participate however 3331 (59%) agreed to a five year follow-up in a multicenter, observational study. Primary end-points included death, myocardial infarction, stroke and optimal medication use over 5 years.</p></div><div><h3>Results</h3><p>Primary end-points including cardiovascular mortality were higher in patients with vascular disease (25.3% vs 15.1%, <em>p</em> <!--><<!--> <!-->0.001, and 13.5 vs 6.2%, <em>p</em> <!--><<!--> <!-->0.001, respectively) and it was doubled in 5 years. Presence of end organ damage further increased the incidence of primary end-point and cardiovascular mortality (30.6% vs 16.2%, <em>p</em> <!--><<!--> <!-->0.001 and 18.1% vs 6.8%, <em>p</em> <!--><<!--> <!-->0.001, respectively). The optimal preventive treatment (statin, renin-angiotensin system blocker, beta-blocker and antiplatelet) rate was low and did not change significantly in 5 years, although the consistent use of angiotensin-converting enzyme inhibitor seemed to be a protective predictor of cardiovascular mortality.</p></div><div><h3>Conclusion</h3><p>In this high risk Turkish population, mortality and morbidity in the medium to long term were high and the implementation rate of optimal preventive treatment unacceptably low. The highest risk subgroup was identified to be those with previous vascular disease/event and end organ damage requiring aggressive medical treatment.</p></div>\",\"PeriodicalId\":11021,\"journal\":{\"name\":\"Cvd Prevention and Control\",\"volume\":\"4 2\",\"pages\":\"Pages 131-138\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.cvdpc.2008.11.001\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cvd Prevention and Control\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S187545700800096X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cvd Prevention and Control","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S187545700800096X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
摘要
背景:尽管来自临床试验的大量证据表明,最新指南推荐的预防措施可显著降低死亡率,但在心血管高危患者中的实施率仍远未达到最佳水平。方法共邀请5600例心血管高危患者参与,其中3331例(59%)同意在一项多中心观察性研究中进行为期5年的随访。主要终点包括死亡、心肌梗死、中风和5年内的最佳用药情况。结果血管疾病患者的主要终点包括心血管死亡率更高(25.3% vs 15.1%, p <0.001, 13.5 vs 6.2%, p <分别为0.001),并且在5年内翻了一番。终末器官损伤的存在进一步增加了主要终点和心血管死亡率的发生率(30.6% vs 16.2%, p <0.001和18.1% vs 6.8%, p <分别为0.001)。最佳预防治疗(他汀类药物、肾素-血管紧张素系统阻滞剂、β -受体阻滞剂和抗血小板)率很低,在5年内没有显著变化,尽管血管紧张素转换酶抑制剂的持续使用似乎是心血管死亡率的保护性预测因子。结论该高危人群中长期死亡率和发病率较高,最佳预防治疗的执行率低得令人难以接受。风险最高的亚组被确定为先前有血管疾病/事件和终末器官损伤需要积极药物治疗的患者。
Five year follow-up of patients with high cardiovascular risk in the Turkish population. What are the predictors of highest cardiovascular risk?
Background
Despite the overwhelming evidence from clinical trials showing that preventive measures recommended by recent guidelines significantly reduce mortality, the implementation rate in patients with high cardiovascular risk is still far from optimal.
Methods
A total of 5600 patients with a high cardiovascular risk were invited to participate however 3331 (59%) agreed to a five year follow-up in a multicenter, observational study. Primary end-points included death, myocardial infarction, stroke and optimal medication use over 5 years.
Results
Primary end-points including cardiovascular mortality were higher in patients with vascular disease (25.3% vs 15.1%, p < 0.001, and 13.5 vs 6.2%, p < 0.001, respectively) and it was doubled in 5 years. Presence of end organ damage further increased the incidence of primary end-point and cardiovascular mortality (30.6% vs 16.2%, p < 0.001 and 18.1% vs 6.8%, p < 0.001, respectively). The optimal preventive treatment (statin, renin-angiotensin system blocker, beta-blocker and antiplatelet) rate was low and did not change significantly in 5 years, although the consistent use of angiotensin-converting enzyme inhibitor seemed to be a protective predictor of cardiovascular mortality.
Conclusion
In this high risk Turkish population, mortality and morbidity in the medium to long term were high and the implementation rate of optimal preventive treatment unacceptably low. The highest risk subgroup was identified to be those with previous vascular disease/event and end organ damage requiring aggressive medical treatment.